Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial  

VANCOUVER, BC, April 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its second quarter financial results for the three months ended February 28, 2021.

In the second quarter, Numinus raised significant funds and advanced its compassionate access trial portfolio, acquisition strategy and innovation agenda while creating a strong foundation for long-term, sustainable growth across all lines of business.

All financial results are reported in Canadian dollars unless otherwise stated.

Q2 2021 Highlights:

Achieved cash balance of $28.5 million as at February 28, 2021Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options Realized net loss of $4.2 million compared to $2.1 million in Q2 2020 Reported revenue of $231,507 compared to $259,489 in Q2 2020 Completed acquisition of Montreal-based Mindspace Wellbeing Signed lab services agreement with Optimi Health to advance R&D Announced collaboration with Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) and key advancements for the compassionate access trial for MDMA-assisted therapy for post-traumatic stress disorder Completed the first legal extraction of Psilocybe mushrooms by a Canadian public company Obtained the Orbitrap Exploris 120 mass spectrometer instrument to accelerate R&D

Highlights Subsequent to Quarter End:

Completed $40.25 million bought deal public financing Raised $1.48 million due to the exercise of warrants and options Achieved several milestones for the compassionate access trial with Syreon Corporation for Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders Received Health Canada license amendment to allow for the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including ketamine, LSD, mescaline, DMT, and MDMA Announced a 7,500-square-foot expansion of Numinus Bioscience’s research laboratory Continued research activities related to psilocybin extraction of Psilocybe mushrooms as part of the Company’s research program Announced Phase 1 clinical trial of natural psilocybin mushroom extraction prepared at Company lab in partnership with KGK Science

Commentary and Outlook

“Q2 was a landmark quarter for Numinus, and we were pleased to close the

Share.

Comments are closed.